AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2020
Mar 24, 2020
30849_dirs_2020-03-24_1bf3436b-e5af-4af9-bfb4-56aac4c2e040.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2020-03-20
Reporting Person: Foley Todd (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-20 | Common Stock | S | 1100 | $15.00 | Disposed | 2361763 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: Shares were sold as follows: 1,058 by BV V and 42 by AM BV5.
F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.00 to $15.01. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Shares are held as follows: 2,273,457 by BV V and 88,306 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.